(ALGS) Aligos Therapeutics - Ratings and Ratios
Capsid Modulator, siRNA, THR-β Agonist, Protease Inhibitor
EPS (Earnings per Share)
Revenue
Dividends
Currently no dividends paid| Risk via 5d forecast | |
|---|---|
| Volatility | 98.2% |
| Value at Risk 5%th | 141% |
| Relative Tail Risk | -12.43% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.76 |
| Alpha | -111.15 |
| CAGR/Max DD | -0.27 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.608 |
| Beta | 2.490 |
| Beta Downside | 3.219 |
| Drawdowns 3y | |
|---|---|
| Max DD | 92.44% |
| Mean DD | 64.77% |
| Median DD | 67.35% |
Description: ALGS Aligos Therapeutics December 22, 2025
Aligos Therapeutics, Inc. (NASDAQ: ALGS) is a clinical-stage biopharma focused on novel small-molecule, capsid-assembly, and siRNA therapeutics targeting viral infections and metabolic liver disease, primarily non-alcoholic steatohepatitis (NASH) and chronic hepatitis B (CHB).
The lead candidate, ALG-055009, is a thyroid-hormone-receptor-β (THR-β) agonist currently in a Phase 2a trial for NASH, a disease with an estimated $30 billion addressable market in the United States by 2028. The company’s CHB pipeline includes ALG-000184 (capsid assembly modulator, completed Phase 1b) and ALG-125755 (siRNA, in Phase I), while ALG-097558 is in Phase 2 for a coronavirus protease inhibitor.
Aligos has secured multiple external partnerships: a discovery and development agreement with Merck for NASH-targeted oligonucleotides; licensing deals with Emory University, Luxna Biotech, and KU Leuven for HBV capsid modulators and coronavirus protease inhibitors; and a clinical collaboration with Xiamen Amoytop Biotech. These collaborations provide both non-dilutive funding and validation of its platform technology.
From a financial perspective, the firm reported a cash runway of roughly 12 months as of Q3 2024 and a cash-burn rate of about $15 million per quarter, reflecting typical R&D intensity for early-stage biotech. The broader biotech sector is experiencing an 8 % YoY increase in R&D spend, driven by heightened investor appetite for gene-editing and RNA-based therapeutics, which could benefit Aligos if its pipeline advances.
For a deeper quantitative view, you may want to explore ValueRay’s analyst dashboard.
Piotroski VR‑10 (Strict, 0-10) 0.5
| Net Income (-86.5m TTM) > 0 and > 6% of Revenue (6% = 158.8k TTM) |
| FCFTA -0.72 (>2.0%) and ΔFCFTA 23.79pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 3078 % (prev 981.6%; Δ 2097 pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA -0.72 (>3.0%) and CFO -79.2m > Net Income -86.5m (YES >=105%, WARN >=100%) |
| NO Net Debt/EBITDA fails (EBITDA <= 0) |
| Current Ratio 4.70 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (10.4m) change vs 12m ago 65.32% (target <= -2.0% for YES) |
| Gross Margin 64.85% (prev 65.67%; Δ -0.81pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 2.67% (prev 6.78%; Δ -4.11pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio -106.8 (EBITDA TTM -84.8m / Interest Expense TTM -814.0k) >= 6 (WARN >= 3) |
Altman Z'' -36.73
| (A) 0.74 = (Total Current Assets 103.4m - Total Current Liabilities 22.0m) / Total Assets 109.8m |
| (B) -5.67 = Retained Earnings (Balance) -622.3m / Total Assets 109.8m |
| warn (B) unusual magnitude: -5.67 — check mapping/units |
| (C) -0.88 = EBIT TTM -87.0m / Avg Total Assets 99.1m |
| (D) -16.39 = Book Value of Equity -621.9m / Total Liabilities 37.9m |
| Total Rating: -36.73 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 41.54
| 1. Piotroski 0.50pt |
| 2. FCF Yield data missing |
| 3. FCF Margin data missing |
| 4. Debt/Equity 0.08 |
| 5. Debt/Ebitda 0.42 |
| 7. RoE -132.4% |
| 8. Rev. Trend -48.97% |
| 9. EPS Trend -52.87% |
What is the price of ALGS shares?
Over the past week, the price has changed by -5.34%, over one month by +2.54%, over three months by +3.27% and over the past year by -76.69%.
Is ALGS a buy, sell or hold?
- Strong Buy: 2
- Buy: 1
- Hold: 0
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the ALGS price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 80.3 | 693.8% |
| Analysts Target Price | 80.3 | 693.8% |
| ValueRay Target Price | 7.9 | -21.9% |
ALGS Fundamental Data Overview December 22, 2025
P/S = 24.8376
P/B = 0.9106
Beta = 2.744
Revenue TTM = 2.65m USD
EBIT TTM = -87.0m USD
EBITDA TTM = -84.8m USD
Long Term Debt = 6.07m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 3.56m USD (from shortTermDebt, last quarter)
Debt = 6.07m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -35.9m USD (from netDebt column, last quarter)
Enterprise Value = -27.3m USD (65.7m + Debt 6.07m - CCE 99.1m)
Interest Coverage Ratio = -106.8 (Ebit TTM -87.0m / Interest Expense TTM -814.0k)
FCF Yield = 291.2% (FCF TTM -79.5m / Enterprise Value -27.3m)
FCF Margin = -3006 % (FCF TTM -79.5m / Revenue TTM 2.65m)
Net Margin = -3268 % (Net Income TTM -86.5m / Revenue TTM 2.65m)
Gross Margin = 64.85% ((Revenue TTM 2.65m - Cost of Revenue TTM 930.0k) / Revenue TTM)
Gross Margin QoQ = 100.0% (prev 73.16%)
Tobins Q-Ratio = -0.25 (set to none) (Enterprise Value -27.3m / Total Assets 109.8m)
Interest Expense / Debt = 210.9% (Interest Expense 12.8m / Debt 6.07m)
Taxrate = -0.18% (negative due to tax credits) (56.0k / -31.5m)
NOPAT = -87.1m (EBIT -87.0m * (1 - -0.18%)) [loss with tax shield] [negative tax rate / tax credits]
Current Ratio = 4.70 (Total Current Assets 103.4m / Total Current Liabilities 22.0m)
Debt / Equity = 0.08 (Debt 6.07m / totalStockholderEquity, last quarter 71.8m)
Debt / EBITDA = 0.42 (negative EBITDA) (Net Debt -35.9m / EBITDA -84.8m)
Debt / FCF = 0.45 (negative FCF - burning cash) (Net Debt -35.9m / FCF TTM -79.5m)
Total Stockholder Equity = 65.3m (last 4 quarters mean from totalStockholderEquity)
RoA = -78.77% (Net Income -86.5m / Total Assets 109.8m)
RoE = -132.4% (Net Income TTM -86.5m / Total Stockholder Equity 65.3m)
RoCE = -121.9% (out of range, set to none) (EBIT -87.0m / Capital Employed (Equity 65.3m + L.T.Debt 6.07m))
RoIC = -133.4% (out of range, set to none) (NOPAT -87.1m / Invested Capital 65.3m)
WACC = 13.91% (E(65.7m)/V(71.8m) * Re(15.19%) + (debt cost/tax rate unavailable))
Discount Rate = 15.19% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -33.33 | Cagr: -9.54%
Fair Price DCF = unknown (Cash Flow -79.5m)
EPS Correlation: -52.87 | EPS CAGR: -5.01% | SUE: -0.83 | # QB: 0
Revenue Correlation: -48.97 | Revenue CAGR: 20.61% | SUE: 0.75 | # QB: 0
EPS next Quarter (2026-03-31): EPS=-2.10 | Chg30d=+0.100 | Revisions Net=+1 | Analysts=2
EPS next Year (2026-12-31): EPS=-7.21 | Chg30d=+0.270 | Revisions Net=+1 | Growth EPS=-3.7% | Growth Revenue=-16.8%
Additional Sources for ALGS Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle